V ancouver, British Columbia – TheNewswire - 28 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), is a clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders. The Company is delighted to report the outcome of a mandatory independent safety audit of its two currently dosing... Read More

Enters i nto Term Sheet t o Acquire Life A I Corp Pty Ltd. Vancouver, British Columbia – TheNewswire - 21 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “ Company ” or “ MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing today announced a major discovery in the effect of psychedelic microdosing on patient’s speech. The Company has discovered it can... Read More

Vancouver, British Columbia – TheNewswire - 15 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), is a clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders. The Company is delighted to provide an update on clinical trial progress and technology developments. MindBio is... Read More

Vancouver, British Columbia – TheNewswire - December 9, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), a leading clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is pleased to announce successful completion of its previously announced private placement and proposed issuance of listed securities in the... Read More

Six months post cessation of treatment with MB22001, the antidepressant response is sustained with an impressive 72% overall reduction in severity of depression with 58% of patients in complete remission from their depression. Vancouver, British Columbia – TheNewswire - 29 October, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), is a leading clinical stage biopharmaceutical... Read More

One of two Phase 2B trials currently dosing and underway: Phase 2B trialing MB22001 in patients with Major Depressive Disorder, and; Phase 2B trialing MB22001 in patients with Advanced Stage Cancer Vancouver, British Columbia – October 24, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), a leading biopharmaceutical company in psychiatric medicine development, targeting... Read More

Vancouver, British Columbia – TheNewswire - 22 OCTOBER, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “ Company ” or “ MindBio ”), is pleased to report that the final milestone in the Company’s Phase 2A Microdosing Depression Clinical Trial, the 6-month post treatment milestone measuring the “severity of depression” has been completed. The completion of this important milestone comes as the Company... Read More

Vancouver, British Columbia – TheNewswire - October 16, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), a leading biopharmaceutical company in psychiatric medicine development, is pleased to provide notice of proposed issuance of listed securities in the Company via private placement to raise up to CAD$200,000 based on a 20 day VWAP or CAD 2.9 cents per share. The Company... Read More

Vancouver, British Columbia – TheNewswire - October 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted to report its microdosing formulation MB22001 has achieved shelf stability at room temperature for 12 months. MB22001 is a proprietary and... Read More

Vancouver, British Columbia – TheNewswire - September 23, 2024 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), a leading biopharmaceutical company in psychiatric medicine development, is delighted to report it has enrolled its 25 th participant into its landmark clinical trial of MB22001 in patients with Major Depressive Disorder. The Company has entered multiple Phase 2B trials... Read More

Vancouver, British Columbia – TheNewswire - 29 August, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “ Company ” or “ MindBio ”), is pleased to provide an update to shareholders. Chief Executive Officer Justin Hanka provides a video update discussing the Company’s clinical trials currently dosing and underway, results from completed trials and plans for the future. The Company has successfully completed... Read More

Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / August 19, 2024 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), a leading biopharmaceutical company in psychiatric medicine development, is delighted to report durability data from Phase 2A... Read More

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood Securities Inc. (" Haywood ") to act as strategic advisor to the Company to support its near-term objectives. Haywood's services will focus on assisting the Company to... Read More

VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), a leading biopharmaceutical company in psychiatric medicine development today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio. Dear Shareholders, We are delighted to provide an update on progress at MindBio, as we head into the second half of... Read More

Rapid, robust, and clinically significant reduction in depression symptoms Trials of MB22001 show substantial improvements in mood, energy, creativity, wellbeing, depression and sleep, including REM sleep. One month post cessation of treatment, the antidepressant response is sustained with a 65% overall reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / June 20, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)... Read More

VANCOUVER, BC / ACCESSWIRE / June 12, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted to report positive secondary data from its world-first take-home microdosing depression trial using MB22001 completed earlier this year. Data from MindBio's Phase 2A... Read More

VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio "), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, presenting MindBio's landmark women's health trials. The trials in women's health aim to address a huge unmet need in effectively treating Pre-Menstrual Syndrome (PMS)... Read More

VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio "), is pleased to announce that it has been presenting MindBio to various parties, institutional investment firms and brokerage firms for a potential dual listing on a senior exchange in the United States or Australia. The Company has successfully completed Phase 1 and Phase 2a Clinical Trials with... Read More

ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in women's health approved for take-home use of MB22001 MB22001 aims to address huge unmet need in the ~25% of women experiencing PMS symptoms MB22001 to be used acutely to address the mood sensitive phases of the menstrual cycle World first clinical trials... Read More

MindBio scientist's sleep research published in prestigious peer reviewed scientific journal MindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio "), a clinical stage biopharma company uniquely pioneering novel... Read More

VANCOUVER, BC / ACCESSWIRE / April 16, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio ") is pleased to announce Riverfort Global Opportunities PCC Ltd has requested to convert CAD$100,000 of its loan to 2,000,000 MindBio shares ("Shares") at $0.05 per Share. All Shares will be subject to a hold period of four-months and one day from the date of issuance under applicable securities... Read More

First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder. Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale), a 60% mean drop in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / March 20, 2024 / MindBio... Read More

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients n=90 Recruitment of clinical trial participants underway Follows successful Phase 2a trial where 53% of depressed patients in complete remission at week 8 of treatment Prior trials of MB22001 show statistically significant improvements in sleep and mood VANCOUVER, BC /... Read More

MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trial Rapid, robust, and clinically significant reduction in depression symptoms Primary efficacy endpoint achieved with an impressive mean 14.1 point drop in Montgomery-Asberg Depression Rating Scale ("MADRS") score After just 8 weeks, patients experienced a 60% reduction in depressive symptoms and 53%... Read More

VANCOUVER, BC / ACCESSWIRE / February 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), a leading biopharma company in psychiatric medicine development, is delighted to announce the completion of its landmark Phase 2a clinical trial in patients with Major Depressive Disorder. MindBio has achieved a significant milestone becoming the only organisation in the world to have... Read More

VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), announces it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio's proprietary titratable form of LSD for... Read More

VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio "), Chief Executive Officer Justin Hanka provides end of year video update on two Phase 2 clinical trials currently underway using MB22001. MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio's proprietary titratable form of LSD... Read More

VANCOUVER, BC / ACCESSWIRE / November 21, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to report two of its team members have been honoured with industry leading awards. Dr Suresh Muthukumaraswamy has been recognised as Academic of the Year. Dr Suresh is MindBio's lead scientific collaborator and creator of MindBio's take home microdosing clinical trials. Co-founder... Read More

World first - approved for take home in cancer patients experiencing emotional distress MB22001 is a proprietary titratable form of LSD (Lysergic Acid Diethylamide) for convenient take-home Microdosing One of two Phase 2 trials currently underway: Phase 2A LSD-Microdosing (MB22001) in patients with Major Depressive Disorder, and; Phase 2B LSD-Microdosing (MB22001) in patients with late stage Cancer VANCOUVER, BC / ACCESSWIRE... Read More

World first - take home trials in cancer patients experiencing emotional distress First doses in patients have been administered A Phase 2B clinical trial assessing the effectiveness of psychedelic (LSD) MB22001 Microdosing with Meaning Centred Psychotherapy in advanced stage cancer patients One of two Phase 2 trials currently underway VANCOUVER, BC / ACCESSWIRE / October 28, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)... Read More

VANCOUVER, BC / ACCESSWIRE / October 26, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to report the Company has been nominated for Company of the Year as well as other profile awards, at the upcoming industry awards (Wonderland, presented by Microdose) to be held in Miami in November. Last year, MindBio and its Chief Executive Officer, Justin Hanka won a number of... Read More

VANCOUVER, BC / ACCESSWIRE / October 24, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (Frankfurt:WF6), (the " Company " or " MindBio"), Chief Executive Officer Justin Hanka provides video update on Phase 2a Depression trial using MB22001. MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio's proprietary titratable form of LSD for at home Microdosing). To date,... Read More

VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to announce that the first ten clinical trial participants (out of a total of 20 anticipated participants) with depression have started take home dosing of MB22001 in the Company's Phase 2a clinical trial. MindBio's LSD-Microdosing clinical trials have obtained regulatory approvals... Read More

VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders. In this video, Justin Hanka, Chief Executive Officer of MindBio, discusses: Progress in MindBio's Phase 2a Microdosing... Read More

Genetic Discovery: MindBio's genetic testing in clinical research yields novel discovery for targeted diagnosis and treatment Significant Intellectual Property & Know How World-first approvals for take-home microdosing in clinical trials VANCOUVER, BC / ACCESSWIRE / September 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to report it has made a major discovery... Read More

World-first take-home approvals The first doses of MB22001 have been administered in an 8 week treatment protocol VANCOUVER, BC / ACCESSWIRE / August 24, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to announce the first doses of MB22001 have been administered to patients in this landmark microdosing study in depressed patients. This trial is a world first and... Read More

MB22001 has been manufactured ready for use in Phase 2 clinical trials World first take-home approvals for psychedelic microdosing VANCOUVER, BC / ACCESSWIRE / August 18, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), is excited to announce it has received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials. MB22001 is a... Read More

World first take-home approvals for LSD-Microdosing in clinical trials in cancer patients LSD-Microdosing combined with clinically proven Meaning Centred Psychotherapy VANCOUVER, BC / ACCESSWIRE / June 25, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to have started selection of participants for its Phase 2 randomized double-blind and placebo controlled clinical... Read More

Patients meeting the selection criteria are currently being pre-screened for entry into the Phase 2 Depression trial Ethics and clinical trials registry approved World first take-home approvals for LSD-Microdosing in clinical trials VANCOUVER, BC / ACCESSWIRE / July 19, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to have started pre-screening for participant entry... Read More

New Discovery: MindBio's LSD-Microdosing Treatment Improves Sleep Significant Intellectual Property Advancement & Know How Completed: Extensive Analysis of LSD-Microdosing Data from 3231 Nights of Sleep Statistically Significant Results: MindBio is pleased to report statistically significant improvements in quality of sleep discovered in the LSD-Microdosing group vs Placebo group VANCOUVER, BC / ACCESSWIRE / June 14, 2023 /... Read More

MindBio and Co-founders profiled in Australian Financial Review Regulatory changes in Australia arrive 1 July 2023 CEO lands in Canada for investor and conference presentations VANCOUVER, BC / ACCESSWIRE / June 9, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio"), is pleased to report that the Company and its Co-Founders Justin Hanka, Chief Executive Officer and Anoosh Manzoori,... Read More

CEO to present at upcoming industry and investor events MindBio scientists to deliver clinical trials results poster presentation at MAPS Psychedelic Science conference in Denver, Colorado Company gathering large interest from both scientific community and investors VANCOUVER, BC / ACCESSWIRE / June 6, 2023 / MindBio Therapeutics Corp. (CSE:MBIO )(Frankfurt:WF6), (the " Company " or " MindBio"), Chief Executive Officer... Read More

1 Million Microdoses used by MindBio to create proprietary microdosing formulation MindBio scientists take delivery of GMP grade LSD Largest clinical trial repository of biometric, physiological and psychometric data for Microdosing in a big data play for MindBio VANCOUVER, BC / ACCESSWIRE / May 30, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio"), Chief Executive Officer Justin... Read More

Ethics approval received for take-home LSD-Microdosing clinical trial in depressed patients Clinical trial has been approved by the Clinical Trials Registry One of two approved take home Phase 2 LSD-Microdosing Clinical Trials running in 2023 VANCOUVER, BC / ACCESSWIRE / May 23, 2023 / MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6), (the " Company " or " MindBio ") is pleased to announce that ethics approval has been... Read More

VANCOUVER, BC / ACCESSWIRE / May 16, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the " Company " or " MindBio", today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio. Dear Shareholders, We are delighted to inform you that MindBio is now trading on the Canadian Securities Exchange (CSE:MBIO) and the Frankfurt Securities Exchange (Frankfurt: WF6), providing... Read More

Ethics approval granted The clinical trial protocol has been submitted for publication and the trial registered A Phase 2 clinical trial assessing the effectiveness of psychedelic (LSD) Microdosing and Meaning Centred Psychotherapy in advanced stage cancer patients One of two Phase 2 LSD-Microdosing Clinical Trials running in 2023 VANCOUVER, BC / ACCESSWIRE / May 11, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (the "... Read More

MindBio clinical trial published in Peer Reviewed Paper Biological Psychiatry First of 8 significant publications on LSD-Microdosing from a Phase 1 clinical trial Phase 1 Clinical trial produced outstanding mood responses in healthy participants MindBio is developing a Microdosing treatment protocol combining big data and drug and formulation development VANCOUVER, BC / ACCESSWIRE / May 9, 2023 / MindBio Therapeutics Corp.... Read More

Leading biotech/biopharm company MindBio lists on the Canadian Securities Exchange Psychedelic medicine fund, Negev Capital is a shareholder Successful completion of Phase 1 trial and two fully funded Phase 2 trials begin shortly World first take-home approvals for LSD-Microdosing clinical trials. VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (the " Company " or " MindBio ") is pleased to... Read More